Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.6.70 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2025. Verfasst von Hideto Osada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Aging and Retinal Biology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Choroidal Neovascularization, Photosensitizing Agents, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study aimed to evaluate the efficacy of photoimmunotherapy (PIT) targeting VEGFR2 for the treatment of neovascular AMD and to investigate its potential as a novel therapeutic strategy.
Methods
DC101-IR700, a conjugate of the anti-mouse VEGFR2 monoclonal antibody DC101 and the photosensitizer IR700, was investigated both in vitro and in vivo. VEGFR2 expression in endothelial cells was confirmed via qPCR and immunocytochemistry. Laser-induced choroidal neovascularization (CNV) was established in C57BL/6J mice. Localization of DC101-IR700 within CNV lesions was assessed by immunofluorescence. After PIT was performed using either a 690 nm near-infrared manual laser or a slit lamp laser, CNV volumes were quantified through confocal microscopy. Cell viability post PIT was measured using MTT assay and cell death in CNV lesions was evaluated using TUNEL staining.
Results
DC101-IR700 localized specifically to VEGFR2-positive cells in CNV lesions, and PIT induced significant VEGFR2-dependent cytotoxicity in vitro. In vivo, both PIT and directional PIT using slit lamp laser significantly reduced CNV volumes compared with controls. TUNEL staining confirmed VEGFR2-specific cell death in treated CNV lesions. Directional PIT achieved similar efficacy to PIT, demonstrating its potential as a clinically viable alternative.
Conclusions
PIT targeting VEGFR2 selectively induced cell death in pathological neovascular tissues, significantly reducing CNV volume in an AMD model. These findings suggest that VEGFR2-specific PIT represents a promising and targeted approach for treating neovascular AMD, offering advantages over conventional anti-VEGF therapies by potentially decreasing treatment frequency and improving efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Aging and Retinal Biology, Keio University School of Medicine, Tokyo, Japan.
- Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
- Tsubota Laboratory, Inc., Tokyo, Japan.
- Laboratory of Photobiology, Keio University School of Medicine, Tokyo, Japan.
Zitieren
APA
Osada, H., Nishimura, T., Mitsunaga, M., Saruta, M., Tsubota, K., Negishi, K., Kurihara, T., & Ban, N. (2025). Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.6.70
Vancouver
Osada H, Nishimura T, Mitsunaga M, Saruta M, Tsubota K, Negishi K, et al. Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.6.70
BibTeX
@article{Osada2025,
author = {Osada, Hideto and Nishimura, Takashi and Mitsunaga, Makoto and Saruta, Masayuki and Tsubota, Kazuo and Negishi, Kazuno and Kurihara, Toshihide and Ban, Norimitsu},
title = {Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.6.70}
}
EUVIMED